OBJECTIVE： To observe the efficacy and safety of neoadjuvant chemotherapy in advanced gastric carcinoma patients before laparoscopic minimally invasive resction. METHODS： In retrospective analysis， 93 patients with advanced gastric carcinoma were divided into single group （55 cases） and combined group （38 cases）. Single group received laparoscopic minimally invasive operation. Combination group was given Tetrahydrofolate injection 400 mg/m2+Oxaliplatin injection 85 mg/m2，i.v.， 2 h， d1+Fluorouracil injection 2 400 mg/m2， i.v.， 46 h， d2. A treatment course lasted for 2 weeks， both received 2-4 courses of treatment and 4 weeks later received laparoscopic minimally invasive resection. Both groups received routine treatment as parenteral nutrition and preventive anti-inflammation. They were given oxaliplatin+capecitabine or gimeracil oteracil potassium capsule+oxaliplatin chemotherapy for 6 courses. Clinical efficacies and ADR of combination group were observed. Operation time， intraoperative blood loss， intraoperative blood transfusion， resection range， conversions to laparotomy， the number of lymph node dissection， complete resection and postoperative first exhaust time， the time of fluid feeding recovery， the length of hospital stay and complications were observed in 2 groups. RESULTS： The objective remission rate and disease control rate of combination group were 44.8％ and 92.2％； there were 23 case time of grade Ⅰ ADR， 13 case time of grade Ⅱ ADR and 3 case time of grade Ⅲ ADR. Complete resection rate of combination group was significantly higher than that of single group， with statistical significance （P＜0.05）. There was no statistical significance in operation time， intraoperative blood loss， intraoperative blood transfusion， resection range， conversions to laparotomy， the number of lymph node dissection， postoperative first exhaust time， the time of fluid feeding recovery， the length of hospital stay or the incidence of complications between 2 groups （P＞0.05）. CONCLUSIONS： For advanced gastric carcinoma patients before laparosapic minimally invasive resection， tetrahydrofolate， oxaliplatin and fluorouracil neoadjuvant chemotherapy show therapeutic efficacy and can improve the rate of complete resection without increasing the incidence of ADR.